Lung Cancer 86 (2014) 91–95
Contents lists available at ScienceDirect
Lung Cancer journal homepage: www.elsevier.com/locate/lungcan
Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan Marcello Tiseo a , Sebastiano Buti a,∗ , Luca Boni b , Roberto Mattioni a , Andrea Ardizzoni a a
Oncology Unit, University Hospital of Parma, Viale Antonio Gramsci, 14, 43126 Parma, Italy Clinical Trials Coordinating Center, Istituto Toscano Tumori Core Research Laboratory, Department of Oncology, University Hospital of Careggi, via Taddeo Alderotti 26/N, 50139 Firenze, Italy b
a r t i c l e
i n f o
Article history: Received 18 June 2014 Received in revised form 19 July 2014 Accepted 25 July 2014 Keywords: Small cell lung cancer Hyponatremia Topotecan Prognostic Second-line Serum sodium (Napl )
a b s t r a c t Objectives: Hyponatremia is reported in about 15% of small cell lung cancer (SCLC). Variable results of the prognostic significance of low plasmatic sodium (Napl ) have been reported. Our study was performed to investigate the prognostic role of hyponatremia in SCLC patients treated in second-line with topotecan chemotherapy. Materials and methods: Data were retrospectively collected from a database including clinical data from 631 patients enrolled in 6 prospective topotecan iv studies. Final data were obtained from 564 patients in which data on baseline Napl were available. Univariate and multivariate analysis were carried out to study the possible correlation between Napl and second-line clinical outcomes. Results: Hyponatremia (Napl < 135 mequiv./l) was present in 101 cases (17.9%). Napl was
Contents lists available at ScienceDirect
Lung Cancer journal homepage: www.elsevier.com/locate/lungcan
Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan Marcello Tiseo a , Sebastiano Buti a,∗ , Luca Boni b , Roberto Mattioni a , Andrea Ardizzoni a a
Oncology Unit, University Hospital of Parma, Viale Antonio Gramsci, 14, 43126 Parma, Italy Clinical Trials Coordinating Center, Istituto Toscano Tumori Core Research Laboratory, Department of Oncology, University Hospital of Careggi, via Taddeo Alderotti 26/N, 50139 Firenze, Italy b
a r t i c l e
i n f o
Article history: Received 18 June 2014 Received in revised form 19 July 2014 Accepted 25 July 2014 Keywords: Small cell lung cancer Hyponatremia Topotecan Prognostic Second-line Serum sodium (Napl )
a b s t r a c t Objectives: Hyponatremia is reported in about 15% of small cell lung cancer (SCLC). Variable results of the prognostic significance of low plasmatic sodium (Napl ) have been reported. Our study was performed to investigate the prognostic role of hyponatremia in SCLC patients treated in second-line with topotecan chemotherapy. Materials and methods: Data were retrospectively collected from a database including clinical data from 631 patients enrolled in 6 prospective topotecan iv studies. Final data were obtained from 564 patients in which data on baseline Napl were available. Univariate and multivariate analysis were carried out to study the possible correlation between Napl and second-line clinical outcomes. Results: Hyponatremia (Napl < 135 mequiv./l) was present in 101 cases (17.9%). Napl was
